Analyzing Spero Therapeutics (NASDAQ:SPRO) & Atrinsic (NASDAQ:PTIX)

Atrinsic (NASDAQ:PTIX) and Spero Therapeutics (NASDAQ:SPRO) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their earnings, valuation, profitability, institutional ownership, analyst recommendations, risk and dividends.

Insider & Institutional Ownership

8.0% of Atrinsic shares are held by institutional investors. Comparatively, 25.6% of Spero Therapeutics shares are held by institutional investors. 8.0% of Atrinsic shares are held by insiders. Comparatively, 5.5% of Spero Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Profitability

This table compares Atrinsic and Spero Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Atrinsic	N/A	N/A	-379.72%
Spero Therapeutics	-108.11%	-125.91%	-57.58%

Analyst Ratings

This is a breakdown of recent recommendations and price targets for Atrinsic and Spero Therapeutics, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Atrinsic	1	0	0	0	1.00
Spero Therapeutics	1	1	0	0	1.50

Earnings and Valuation

This table compares Atrinsic and Spero Therapeutics”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Atrinsic	N/A	N/A	-$5.53 million	($7.95)	-0.06
Spero Therapeutics	$47.98 million	2.60	-$68.57 million	($0.79)	-2.80

Atrinsic has higher earnings, but lower revenue than Spero Therapeutics. Spero Therapeutics is trading at a lower price-to-earnings ratio than Atrinsic, indicating that it is currently the more affordable of the two stocks.

Volatility and Risk

Atrinsic has a beta of 1.11, meaning that its share price is 11% more volatile than the S&P 500. Comparatively, Spero Therapeutics has a beta of 1.45, meaning that its share price is 45% more volatile than the S&P 500.

Summary

Spero Therapeutics beats Atrinsic on 6 of the 11 factors compared between the two stocks.

About Atrinsic

Protagenic Therapeutics, Inc., a biopharmaceutical company, engages in the discovery and development of therapeutics to treat stress-related neuropsychiatric and mood disorders. Its lead compound comprises PT00114, a synthetic form of teneurin carboxy-terminal associated peptide, an endogenous brain signaling peptide that can dampen overactive stress responses. Protagenic Therapeutics, Inc. is headquartered in New York, New York.

About Spero Therapeutics

Spero Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on identifying, developing, and commercializing novel treatments for multi-drug resistant (MDR) bacterial infections and rare diseases in the United States. The company’s product candidates include tebipenem pivoxil hydrobromide (HBr), an oral carbapenem-class antibiotic to treat complicated urinary tract infections, including pyelonephritis for adults; SPR206, an intravenous-administered antibiotic against MDR Gram-negative pathogens comprising carbapenem-resistant enterobacterales (CRE), acinetobacter baumannii, and pseudomonas aeruginosa, as well as negative bacterial infections in the hospital setting; and SPR720, a novel oral antibiotic agent for the treatment of non-tuberculous mycobacterial pulmonary disease. It has license agreement with Meiji Seika Pharma Co., Ltd. to support the development of tebipenem HBr; Everest Medicines to develop, manufacture, and commercialize SPR206 in Greater China, South Korea, and Southeast Asian countries; and Vertex Pharmaceuticals Incorporated for patents relating to SPR720, as well as SPR719, an active metabolite. Spero Therapeutics, Inc. was founded in 2013 and is headquartered in Cambridge, Massachusetts.